This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There’s a gap between the supply of digital health tools that hospitals and health systems offer patients, and what patients-as-consumers need for overall health and wellbeing. Health Populi’s Hot Points: The HIMSS-CCM research focused on “digital patientexperience.”
Digging deeper into some of the big trends, Shelly’s observations will also ring authentic to health/care stakeholders… AI is everywhere at CES. As my friends at #JPM this week are hearing in San Francisco, AI is part of virtually every biotech and med-tech story. But it’s not necessarily useful for everything.
What’s underneath that macro “healthcare” index number of 67 is a precipitous decline in the past year for Americans’ trust in hospitals, compared with biotech, pharma, consumer healthcare, and even health insurance — all of which grew in trust between 2018 and 2019, but not so with the hospital segment of U.S.
To address that challenge, in 2017 PLM secured a $100 million (controlling interest) investment from iCarbonX , a Chinese company that is amassing patient data to discover cures for disease. When this occurred, it didn’t cause more than a ripple of interest outside biotech. But the U.S. citizens’ personal data.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content